Maravai LifeSciences Holdings Inc.
Organization details
- Legal name
- Maravai LifeSciences Holdings Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- SAN Diego
- Headquarters state / province
- California
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- MRVI
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001823239
Board of directors
-
Anat Ashkenazi · DirectorSince 2023
-
Benjamin James Daverman · DirectorSince 2023
-
Bernd Brust · Director · Chief Executive OfficerSince 2025
-
Carl Hull · Director · See RemarksSince 2023
-
Constantine S. Mihas · DirectorSince 2023
-
Gregory T. Lucier · DirectorSince 2023
-
Jessica Hopfield · DirectorSince 2023
-
John A. DeFord · DirectorSince 2023
-
Luke Joseph Marker · DirectorSince 2023
-
Murali Prahalad · DirectorSince 2023
-
R. Andrew Eckert · DirectorSince 2024
-
Sean Laurence Cunningham · DirectorSince 2023
-
Susannah Gray · DirectorSince 2023
Chief executives
Weak · grade F
Out of 100, from shareholder return, dividends, growth and acquisitions.
Partial: only 20% of the scoring weight is on file.
- Revenue growth 20%
- 0
-28.3% a year in revenue
20% of the scoring weight is on file. Figures cover December 2024 – December 2025.
Director election results
Annual meeting of May 18, 2023. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
79.4%
-
80.6%
-
80.8%
Board connections
7 of this board's directors also sit on 11 other boards.
- via Constantine S. Mihas and Sean Laurence Cunningham
- via Susannah Gray
- via Susannah Gray
- via Gregory T. Lucier
- via R. Andrew Eckert
- via Gregory T. Lucier
- via Jessica Hopfield
- via R. Andrew Eckert
- via John A. DeFord
- via Jessica Hopfield
- via John A. DeFord
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $1,880,244
- 5 purchases by 2 insiders
- Sold, last 12 months
- $254,000
- 2 sales by 1 insider
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Sep 8, 2026 | Bernd Brust Director, Officer (Chief Executive Officer) | Shares withheld for tax | −29,250 | $7.32 | $214,110 |
| Aug 31, 2026 | Rajesh Asarpota Officer (Chief Financial Officer) | Shares withheld for tax | −5,465 | $7.68 | $41,971 |
| Aug 10, 2026 | Bernd Brust Director, Officer (Chief Executive Officer) | Shares withheld for tax | −29,250 | $6.23 | $182,228 |
| Jul 30, 2026 | Rajesh Asarpota Officer (Chief Financial Officer) | Shares withheld for tax | −5,465 | $6.59 | $36,014 |
| Jul 8, 2026 | Bernd Brust Director, Officer (Chief Executive Officer) | Shares withheld for tax | −29,250 | $5.92 | $173,160 |
| Jun 30, 2026 | Rajesh Asarpota Officer (Chief Financial Officer) | Shares withheld for tax | −65,584 | $6.39 | $419,082 |
| Jun 10, 2026 | ORESHACK KURT Officer (General Counsel) | Open-market sale | −25,000 | $5.10 | $127,500 |
| Jun 9, 2026 | ORESHACK KURT Officer (General Counsel) | Open-market sale | −25,000 | $5.06 | $126,500 |
| Jun 9, 2026 | Gregory T. Lucier Director | Gift | −46,293 | — | — |
| Jun 9, 2026 | Gregory T. Lucier Director | Gift | +46,293 | — | — |
| Jun 8, 2026 | Bernd Brust Director, Officer (Chief Executive Officer) | Shares withheld for tax | −351,001 | $5.02 | $1,762,025 |
| May 26, 2026 | Luke Joseph Marker Director | Grant or award | +46,293 | — | — |
| May 26, 2026 | Susannah Gray Director | Grant or award | +46,293 | — | — |
| May 26, 2026 | Constantine S. Mihas Director | Grant or award | +46,293 | — | — |
| May 26, 2026 | R. Andrew Eckert Director | Grant or award | +46,293 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.